Platinum OpinionPSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies
Section snippets
Conflicts of interest
Creation of the images in this manuscript involved the administration of 18F-DCFPyL, a PSMA-targeted PET radiotracer that is being investigated under a US Food and Drug Administration investigational new drug application (IND 121064). Martin G. Pomper is a co-inventor on a US patent covering 18F-DCFPyL, and is thus entitled to a portion of any licensing fees and royalties generated by this technology. Michael A. Gorin has served as a consultant to Progenics Pharmaceuticals, the licensee of 18
References (11)
- et al.
“Gotta catch ‘em all”, or do we? Pokemet approach to metastatic prostate cancer
Eur Urol
(2017) - et al.
PI-RADS Prostate Imaging-Reporting and Data System: 2015, version 2
Eur Urol
(2016) - et al.
Correlation of PSMA-targeted 18F-DCFPyL PET/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer
Clin Genitourin Cancer
(2017) - et al.
Radiologists may be accountable for containing Medicare costs and spending under MACRA
J Am Coll Radiol
(2017) - et al.
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
J Nucl Med
(2012)
There are more references available in the full text version of this article.
Cited by (97)
A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging
2024, Seminars in Nuclear MedicineHow to Report PSMA PET
2024, Seminars in Nuclear Medicine<sup>18</sup>F-DCFPyL PET/CT guidelines
2023, Revista Espanola de Medicina Nuclear e Imagen Molecular
© 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.